ClinVar Genomic variation as it relates to human health
NM_016824.5(ADD3):c.1100G>A (p.Gly367Asp)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_016824.5(ADD3):c.1100G>A (p.Gly367Asp)
Variation ID: 242273 Accession: VCV000242273.7
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 10q25.2 10: 110122249 (GRCh38) [ NCBI UCSC ] 10: 111882007 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Jul 3, 2016 Mar 10, 2024 Jul 9, 2020 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_016824.5:c.1100G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_058432.1:p.Gly367Asp missense NM_001121.4:c.1100G>A NP_001112.2:p.Gly367Asp missense NM_001320591.2:c.1100G>A NP_001307520.1:p.Gly367Asp missense NM_001320592.2:c.1100G>A NP_001307521.1:p.Gly367Asp missense NM_001320593.2:c.1100G>A NP_001307522.1:p.Gly367Asp missense NM_001320594.2:c.866G>A NP_001307523.1:p.Gly289Asp missense NM_019903.5:c.1100G>A NP_063968.1:p.Gly367Asp missense NC_000010.11:g.110122249G>A NC_000010.10:g.111882007G>A NG_051033.1:g.130900G>A Q9UEY8:p.Gly367Asp - Protein change
- G367D, G289D
- Other names
- -
- Canonical SPDI
- NC_000010.11:110122248:G:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
-
effect on protein activity; Variation Ontology [ VariO:0053]
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.00020 (A)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
1000 Genomes Project 30x 0.00016
1000 Genomes Project 0.00020
Trans-Omics for Precision Medicine (TOPMed) 0.00000
Exome Aggregation Consortium (ExAC) 0.00001
The Genome Aggregation Database (gnomAD) 0.00001
The Genome Aggregation Database (gnomAD), exomes 0.00001
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
ADD3 | - | - |
GRCh38 GRCh37 |
187 | 217 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic/Likely pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Jul 9, 2020 | RCV000231295.7 | |
Pathogenic (1) |
no assertion criteria provided
|
- | RCV000234930.1 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Jun 01, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Cerebral palsy, spastic quadriplegic, 3
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Institute of Human Genetics, University of Leipzig Medical Center
Accession: SCV001443001.1
First in ClinVar: Nov 14, 2020 Last updated: Nov 14, 2020 |
Comment:
PS3, PM2, PM3, PP1_Moderate
|
|
Likely pathogenic
(Jul 09, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Cerebral palsy, spastic quadriplegic, 3
Affected status: yes
Allele origin:
unknown
|
Baylor Genetics
Accession: SCV001520238.1
First in ClinVar: Mar 22, 2021 Last updated: Mar 22, 2021 |
Comment:
This variant was determined to be likely pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
|
|
Pathogenic
(Apr 30, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Cerebral palsy, spastic quadriplegic, 3
Affected status: yes
Allele origin:
germline
|
Centogene AG - the Rare Disease Company
Accession: SCV002059435.1
First in ClinVar: Jan 14, 2022 Last updated: Jan 14, 2022 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: literature only
|
Cerebral palsy
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
ClinVar Staff, National Center for Biotechnology Information (NCBI)
Accession: SCV000282045.1
First in ClinVar: Jul 10, 2016 Last updated: Jul 10, 2016 |
Number of individuals with the variant: 4
Clinical Features:
Frontotemporal cerebral atrophy (present) , Ventriculomegaly (present)
Sex: mixed
Geographic origin: Jordan
|
|
Pathogenic
(Feb 15, 2024)
|
no assertion criteria provided
Method: literature only
|
CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000291923.3
First in ClinVar: Jul 03, 2016 Last updated: Mar 10, 2024 |
Comment on evidence:
In 4 sibs, born of consanguineous Jordanian parents, with spastic quadriplegic cerebral palsy-3 (CPSQ3; 617008), Kruer et al. (2013) identified a homozygous c.1100G-A transition (c.1100G-A, … (more)
In 4 sibs, born of consanguineous Jordanian parents, with spastic quadriplegic cerebral palsy-3 (CPSQ3; 617008), Kruer et al. (2013) identified a homozygous c.1100G-A transition (c.1100G-A, ENST00000356080) in the ADD3 gene, resulting in a gly367-to-asp (G367D) substitution in the putative oligomerization domain. The mutation, which was found by a combination of homozygosity mapping and exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family. The mutation was not found in 208 ethnically matched Middle Eastern controls and 450 mixed European controls. Lysates from patient fibroblasts showed a significant increase in actin polymerization compared to controls, consistent with impaired actin capping activity and a loss of function. Knockdown of the ADD3 transcript using siRNA resulted in similarly impaired actin capping. Compared to controls, mutant fibroblast showed a lack of neurite-like processes and increased proliferation and migration. The mutation also impaired the ability of mutant ADD3 to associate with the ADD1 (102680) subunit. Overall, the biologic studies implicated abnormalities of components of the dynamic cytoskeleton and process outgrowth in neuromotor dysfunction. By whole-exome sequencing in a patient, born to consanguineous parents, with CPSQ3, Theunissen et al. (2018) identified homozygosity for the G367D mutation in the ADD3 gene. Functional studies in patient cells were not performed. In a Syrian patient, born to consanguineous parents, with CPSQ3, Sanchez Marco et al. (2022) identified homozygosity for the G367D mutation in the ADD3 gene. The mutation, which was identified by whole-exome sequencing, was present in heterozygous state in the parents. (less)
|
Germline Functional Evidence
Functional
Help
The functional consequence of the variant, based on experimental evidence and provided by the submitter. consequence |
Method
Help
A brief description of the method used to determine the functional consequence of the variant. A citation for the method is included, when provided by the submitter. |
Result
Help
A brief description of the result of this method for this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting functional evidence for the germline classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
---|---|---|---|---|
effect on protein activity
|
|
|
ClinVar Staff, National Center for Biotechnology Information (NCBI)
Accession: SCV000282045.1
|
|
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Hereditary spastic paraparesis presenting as cerebral palsy due to ADD3 variant with mechanistic insight provided by a Drosophila γ-adducin model. | Sanchez Marco SB | Clinical genetics | 2022 | PMID: 36046955 |
Whole Exome Sequencing Is the Preferred Strategy to Identify the Genetic Defect in Patients With a Probable or Possible Mitochondrial Cause. | Theunissen TEJ | Frontiers in genetics | 2018 | PMID: 30369941 |
Mutations in γ adducin are associated with inherited cerebral palsy. | Kruer MC | Annals of neurology | 2013 | PMID: 23836506 |
Text-mined citations for rs564185858 ...
HelpRecord last updated Mar 11, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.